Word

ULTRAGENYX GENE THERAPY

Status

Dead

Status Code

602

Status Date

Friday, March 31, 2023

Serial Number

97353471

Mark Type

3000

Filing Date

Friday, April 8, 2022

Abandoned Date

Wednesday, March 15, 2023

Trademark Owner History

Ultragenyx Pharmaceutical Inc.

Classifications

5 Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, inflammatory, autoimmune, musculoskeletal, ophthalmologic, respiratory, and hematologic diseases and disorders

1 Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, all for in-vivo laboratory use in gene therapy

44 Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders

42 Biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays

The mark consists of the word "ultragenyx" in lower case letters above the words "gene therapy". The formative "ultra" and the words "gene therapy" are purple and the formative "genyx" is green. The letter "x" in "genyx" is stylized and features an enlongated stroke reaching above and below the word "ultragenyx". A gray hexagon is below the formative "ultra" and to the left of the words "gene therapy." A double helix, one strand of which is purple and one strand of which is green, is vertically oriented inside the gray hexagon.
Color is not claimed as a feature of the mark.

Trademark Events

Mar 31, 2023

Abandonment Notice E-Mailed - Failure To Respond

Mar 31, 2023

Abandonment Notice Mailed - Failure To Respond

Mar 31, 2023

Abandonment - Failure To Respond Or Late Response

Dec 14, 2022

Notification Of Non-Final Action E-Mailed

Dec 14, 2022

Non-Final Action E-Mailed

Dec 14, 2022

Non-Final Action Written

Dec 12, 2022

Assigned To Examiner

Apr 13, 2022

Notice Of Design Search Code E-Mailed

Apr 12, 2022

New Application Office Supplied Data Entered

Apr 12, 2022

New Application Entered